Exact Sciences Competitors

Exact Sciences (NASDAQ:EXAS) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Earnings and Valuation

This table compares Exact Sciences and Amgen's revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Exact Sciences and Amgen, as reported by MarketBeat.com.

Exact Sciences currently has a consensus price target of $150.3333, indicating a potential upside of 19.75%. Amgen has a consensus price target of $259.4091, indicating a potential upside of 4.20%. Given Exact Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Exact Sciences is more favorable than Amgen.

Profitability

This table compares Exact Sciences and Amgen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

90.4% of Exact Sciences shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 1.8% of Exact Sciences shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Exact Sciences has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Summary

Amgen beats Exact Sciences on 8 of the 14 factors compared between the two stocks.

Exact Sciences (NASDAQ:EXAS) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Insider and Institutional Ownership

90.4% of Exact Sciences shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 1.8% of Exact Sciences shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Exact Sciences and Gilead Sciences, as reported by MarketBeat.com.

Exact Sciences currently has a consensus price target of $150.3333, indicating a potential upside of 19.75%. Gilead Sciences has a consensus price target of $97.2308, indicating a potential upside of 49.33%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Exact Sciences.

Profitability

This table compares Exact Sciences and Gilead Sciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Exact Sciences and Gilead Sciences' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Exact Sciences has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Summary

Gilead Sciences beats Exact Sciences on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Profitability

This table compares Vertex Pharmaceuticals and Exact Sciences' net margins, return on equity and return on assets.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Exact Sciences' gross revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Vertex Pharmaceuticals and Exact Sciences, as provided by MarketBeat.

Vertex Pharmaceuticals currently has a consensus target price of $293.1250, indicating a potential upside of 37.39%. Exact Sciences has a consensus target price of $150.3333, indicating a potential upside of 19.75%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Exact Sciences.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 90.4% of Exact Sciences shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Exact Sciences on 12 of the 15 factors compared between the two stocks.

Exact Sciences (NASDAQ:EXAS) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Valuation and Earnings

This table compares Exact Sciences and Regeneron Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Exact Sciences and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

90.4% of Exact Sciences shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 1.8% of Exact Sciences shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Exact Sciences has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Exact Sciences and Regeneron Pharmaceuticals, as provided by MarketBeat.

Exact Sciences currently has a consensus target price of $150.3333, suggesting a potential upside of 19.75%. Regeneron Pharmaceuticals has a consensus target price of $637.2083, suggesting a potential upside of 34.10%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Exact Sciences.

Summary

Regeneron Pharmaceuticals beats Exact Sciences on 12 of the 15 factors compared between the two stocks.

Exact Sciences (NASDAQ:EXAS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.

Institutional and Insider Ownership

90.4% of Exact Sciences shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 1.8% of Exact Sciences shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Exact Sciences and Biogen, as reported by MarketBeat.com.

Exact Sciences currently has a consensus target price of $150.3333, suggesting a potential upside of 19.75%. Biogen has a consensus target price of $303.5517, suggesting a potential upside of 13.19%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Exact Sciences is more favorable than Biogen.

Earnings & Valuation

This table compares Exact Sciences and Biogen's gross revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Exact Sciences has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Profitability

This table compares Exact Sciences and Biogen's net margins, return on equity and return on assets.

Summary

Biogen beats Exact Sciences on 8 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Exact Sciences (NASDAQ:EXAS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 90.4% of Exact Sciences shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Exact Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Earnings and Valuation

This table compares Alexion Pharmaceuticals and Exact Sciences' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Exact Sciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Alexion Pharmaceuticals and Exact Sciences, as reported by MarketBeat.com.

Alexion Pharmaceuticals currently has a consensus target price of $153.8636, indicating a potential downside of 0.74%. Exact Sciences has a consensus target price of $150.3333, indicating a potential upside of 19.75%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Exact Sciences is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Exact Sciences on 9 of the 15 factors compared between the two stocks.